APA (7th ed.) Citation

S, K., S, K., & H, L. (2020). A critical review of the United States regulatory pathways for determining the equivalence of efficacy between CT-P13 and original infliximab (Remicade®). Dove Medical Press.

Chicago Style (17th ed.) Citation

S, Kim, Kim S, and Lee H. A Critical Review of the United States Regulatory Pathways for Determining the Equivalence of Efficacy Between CT-P13 and Original Infliximab (Remicade®). Dove Medical Press, 2020.

MLA (9th ed.) Citation

S, Kim, et al. A Critical Review of the United States Regulatory Pathways for Determining the Equivalence of Efficacy Between CT-P13 and Original Infliximab (Remicade®). Dove Medical Press, 2020.